Canada markets open in 17 minutes

Equillium, Inc. (0FY.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.4625-0.0415 (-8.23%)
As of 09:15AM CET. Market open.
Full screen
Previous Close0.5040
Open0.4625
Bid0.4915 x 0
Ask0.5100 x 0
Day's Range0.4625 - 0.4625
52 Week Range0.4035 - 1.5600
Volume7,500
Avg. Volume232
Market Cap16.243M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-0.2000
Earnings DateNov 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
  • PR Newswire

    EQ Bank Card launches in Québec as Carte Banque EQ

    EQ Bank (Banque EQ in Québec) is offering Québec customers a new way to earn, save and spend their money, with the introduction of its popular EQ Bank Card1 (Carte Banque EQ). Customers can use the card to withdraw cash for free at any ATM in the country, earn cash back on their spending, earn high interest on their card balance, and travel without paying foreign currency conversion fees.

  • Business Wire

    Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

    LA JOLLA, Calif., November 13, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study evaluating itolizumab in lupus nephritis patients was presented at ACR Convergence, the annual meeting of the American College of Rheumatology (ACR). The data presented by Dr. Kenneth Kalunian, Professor, Medicine, UCSD School

  • Business Wire

    Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

    LA JOLLA, Calif., November 08, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2023 and provided corporate and clinical development updates.